In a market where biotech usually gets lumped into either “future cure” or “eternal underdog,” GSK (GSK) is carving out a third category: cash-flowing, specialty-driven, and still misunderstood. It’s not the hottest name in oncology. It’s not a dividend aristocrat either. But if you’re looking for where the next rerating in big pharma might come […]
Tag Archives: (SNY)
Mad Hedge Biotech and Healthcare Letter June 3, 2025 Fiat Lux Featured Trade: (WHEN BIG PHARMA DREAMS GO UP IN SMOKE) (SNY), (REGN), (AAPL)
- 1
- 2